Literature DB >> 16955688

Drug evaluation: bevirimat--HIV Gag protein and viral maturation inhibitor.

Zelalem Temesgen1, Judith E Feinberg.   

Abstract

Panacos Pharmaceuticals Inc is developing the HIV Gag protein and viral maturation inhibitor bevirimat for the potential oral treatment of HIV infection. Phase II clinical trials are underway and phase III trials expected to commence in 2007.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16955688

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  6 in total

1.  Discovery of BMS-955176, a Second Generation HIV-1 Maturation Inhibitor with Broad Spectrum Antiviral Activity.

Authors:  Alicia Regueiro-Ren; Zheng Liu; Yan Chen; Ny Sin; Sing-Yuen Sit; Jacob J Swidorski; Jie Chen; Brian L Venables; Juliang Zhu; Beata Nowicka-Sans; Tricia Protack; Zeyu Lin; Brian Terry; Himadri Samanta; Sharon Zhang; Zhufang Li; Brett R Beno; Xiaohua S Huang; Sandhya Rahematpura; Dawn D Parker; Roy Haskell; Susan Jenkins; Kenneth S Santone; Mark I Cockett; Mark Krystal; Nicholas A Meanwell; Umesh Hanumegowda; Ira B Dicker
Journal:  ACS Med Chem Lett       Date:  2016-04-22       Impact factor: 4.345

Review 2.  HIV-1 Gag as an Antiviral Target: Development of Assembly and Maturation Inhibitors.

Authors:  Paul Spearman
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

3.  Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors.

Authors:  Zeyu Lin; Joseph Cantone; Hao Lu; Beata Nowicka-Sans; Tricia Protack; Tian Yuan; Hong Yang; Zheng Liu; Dieter Drexler; Alicia Regueiro-Ren; Nicholas A Meanwell; Mark Cockett; Mark Krystal; Max Lataillade; Ira B Dicker
Journal:  PLoS Pathog       Date:  2016-11-28       Impact factor: 6.823

4.  The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor-Resistant Clinical Isolates.

Authors:  Neelanjana Ray; Tianbo Li; Zeyu Lin; Tricia Protack; Petronella Maria van Ham; Carey Hwang; Mark Krystal; Monique Nijhuis; Max Lataillade; Ira Dicker
Journal:  J Acquir Immune Defic Syndr       Date:  2017-05-01       Impact factor: 3.731

5.  Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage.

Authors:  Beata Nowicka-Sans; Tricia Protack; Zeyu Lin; Zhufang Li; Sharon Zhang; Yongnian Sun; Himadri Samanta; Brian Terry; Zheng Liu; Yan Chen; Ny Sin; Sing-Yuen Sit; Jacob J Swidorski; Jie Chen; Brian L Venables; Matthew Healy; Nicholas A Meanwell; Mark Cockett; Umesh Hanumegowda; Alicia Regueiro-Ren; Mark Krystal; Ira B Dicker
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

6.  Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial.

Authors:  Javier Morales-Ramirez; Johannes R Bogner; Jean-Michel Molina; Johan Lombaard; Ira B Dicker; David A Stock; Michelle DeGrosky; Margaret Gartland; Teodora Pene Dumitrescu; Sherene Min; Cyril Llamoso; Samit R Joshi; Max Lataillade
Journal:  PLoS One       Date:  2018-10-23       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.